Abstract: The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.
Type:
Application
Filed:
May 9, 2012
Publication date:
February 28, 2013
Applicant:
PERVASIS THERAPEUTICS, INC.
Inventors:
Helen Marie Nugent, Elazer Edelman, Stephen Bollinger
Abstract: Disclosed herein are materials and methods suitable for treating injured, damaged or diseased mineralized and non-mineralized skeletal tissues, including bones, joints, tendons, ligaments, cartilage and/or other non-mineralized skeletal tissues. The affected structure can be treated by contacting a surface of the skeletal element at or adjacent to or in the vicinity of an area of injury, damage or disease with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected structure. A composition comprising a biocompatible matrix and cells engrafted therein or thereon can be used to treat the affected structure. The composition can be a flexible planar material or a flowable composition.
Type:
Application
Filed:
August 8, 2008
Publication date:
March 24, 2011
Applicant:
PERVASIS THERAPEUTICS, INC.
Inventors:
Helen Marie Nugent, Yin Shan Ng, Robert Thin Tham Sjin, Shai Schubert, James Richard Birkhead
Abstract: Disclosed herein are materials and methods suitable for treating and managing plaque disease, including vulnerable plaque. An implantable material comprising cells, such as but not limited to endothelial cells, and a biocompatible matrix can reduce progression or deterioration of a plaque-associated lesion situated on the interior lumen of said blood vessel. The implantable material is implanted directly on an exterior surface of a blood vessel at or adjacent or in the vicinity of the site of a lesion on an interior lumen. Alternatively, the implantable material is deposited on an exterior surface at or adjacent or in the vicinity of the site of a lesion on an interior lumen by an intraluminal delivery device which traverses or penetrates the vessel wall or by a percutaneous delivery device which enters the perivascular space. Both modes of administration can be preceded by or coincident with an imaging step.
Type:
Application
Filed:
September 13, 2010
Publication date:
February 24, 2011
Applicant:
PERVASIS THERAPEUTICS, INC.
Inventors:
Elazer Edelman, Anupam Dalal, Helen Marie Nugent, Steve Bollinger
Abstract: The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.
Type:
Application
Filed:
September 13, 2010
Publication date:
January 6, 2011
Applicant:
PERVASIS THERAPEUTICS, INC.
Inventors:
Helen Marie Nugent, Elazer Edelman, Steve Bollinger
Abstract: The present invention relates to a device for delivering a flowable composition comprising cells, wherein the flowable composition is in an amount effective to treat an injured or diseased site. The device comprises a delivery device adapted for minimally-invasive delivery of the flowable composition through which the flowable composition can be passed while maintaining the effectiveness and viability of the cells of the flowable composition. The present invention further relates to a method for delivering the flowable composition comprising cells. The method comprises the steps of percutaneously inserting a delivery device adapted for minimally-invasive delivery of the flowable composition through which the flowable composition can be passed while maintaining the effectiveness and viability of the cells of the flowable composition and administering the flowable composition at, adjacent to or in the vicinity of the injured or diseased site.
Type:
Application
Filed:
June 13, 2008
Publication date:
July 22, 2010
Applicant:
PERVASIS THERAPEUTICS, INC.
Inventors:
Glenn Kanner, Stephen August Bollinger, Helen Marie Nugent, Celina Choi, Desmond White, Yin Shan Ng
Abstract: Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.
Type:
Application
Filed:
April 21, 2006
Publication date:
April 2, 2009
Applicant:
Pervasis Therapeutics, Inc.
Inventors:
Elazer R. Edelman, Helen Marie Nugent, Heiko Methe